ClinACE has announced its long term collaboration with a renowned stem cell banking and therapy company, for conducting end-to-end clinical development programme for all their stem cell therapy. ClinACE has already commenced a clinical study initiation for the sponsor involving stem cell therapy for patients with Type II diabetes.
“This partnership aims to enhance the quality and accelerate the clinical development activities of stem cell therapies. We remain adherent to our strategy of ‘cost-effective coupled with qualitative productivity, as we expand into the pharmaceutical, device and biotech research industry,” said Jayesh Chaudhary, Chief Executive Officer, ClinACE.
The ICMR has laid down clear guidelines for the conduct of clinical studies involving stem cells. Every aspect of these studies is approved and monitored by the Institutional Committee of Stem Cell Research (IC-SCR) and National Apex Committee of Stem Cell Research (NAC-SCR). ClinACE has planned its clinical development programme involving stem cell research, in complete adherence to these guidelines.
The last few years has seen a remarkable growth in the stem cell research segment. According to a report by Research and Markets, the global stem cell market is estimated to be $88.3 billion by 2014, growing at a CAGR of 14.8 per cent from 2009 to 2014. Given the upward trends in this industry, ClinACE has designed its future business plan duly offering its services to the biopharma market.
Stem cell studies represent the dynamic and fascinating realm of regenerative medicine. Being an upcoming and a challenging therapeutic area, the team at ClinACE has begun work on this project with great enthusiasm.
EP News Bureau